Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 8/20 | 0.33 |
| ▸ | FEN1 | P39748 | 8/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144324 | 0.81 | — | — | |
| SCHEMBL11954930 | 0.75 | ALOX5AP (0.34) | ALOX5APFEN1AAK1MEN1ALDH1A1 | |
| SCHEMBL24453275 | 0.74 | IDH1 (0.38) | ALOX5APFEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL21718461 | 0.74 | MEN1 (0.35) | ALOX5APFEN1AAK1MEN1ALDH1A1 | |
| SCHEMBL22308085 | 0.74 | CCR1 (0.37) | AAK1 | |
| SCHEMBL22543805 | 0.74 | ALOX5AP (0.33) | ALOX5APFEN1MEN1ALDH1A1KMT2A | |
| SCHEMBL24597184 | 0.73 | LOXL2 (0.30) | — | |
| SCHEMBL3104097 | 0.72 | MEN1 (0.34) | ALOX5APFEN1MEN1ALDH1A1KMT2A | |
| SCHEMBL18590248 | 0.72 | ALOX5AP (0.39) | ALOX5APFEN1AAK1 | |
| SCHEMBL11955164 | 0.72 | AAK1 (0.34) | ALOX5APFEN1AAK1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | ALOX5AP 3125/4885FEN1 3865/4885AAK1 2504/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ALOX5AP 2740/4885FEN1 3365/4885AAK1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.